You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Dow
Mallinckrodt
Harvard Business School
Colorcon

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,339,466

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,339,466 protect, and when does it expire?

Patent 9,339,466 protects TPOXX and is included in one NDA.

This patent has thirty-nine patent family members in nineteen countries.

Summary for Patent: 9,339,466
Title:Polymorphic forms of ST-246 and methods of preparation
Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocy- cloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
Inventor(s): Tyavanagimatt; Shanthakumar R. (Corvallis, OR), Stone; Melialani A. C. L. (Corvallis, OR), Weimers; William C. (Corvallis, OR), Nelson; Dylan (Portland, OR), Bolken; Tove' C. (Keizer, OR), Hruby; Dennis E. (Albany, OR), O'Neill; Michael H. (Painesville, OH), Sweetapple; Gary (Madison, OH), McCloughan; Kelley A. (South Haven, MI)
Assignee: SIGA TECHNOLOGIES, INC. (Corvallis, OR)
Application Number:13/069,813
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,339,466

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,339,466

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 3221   Start Trial
Argentina 083435   Start Trial
Australia 2011232551   Start Trial
Brazil 112012023743   Start Trial
Canada 2793533   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Boehringer Ingelheim
Medtronic
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.